TD Cowen Upgrades Ascendis Pharma to Buy, Raises Price Target to $175
Portfolio Pulse from Benzinga Newsdesk
TD Cowen has upgraded Ascendis Pharma (NASDAQ:ASND) from Hold to Buy and raised the price target from $156 to $175.
June 25, 2024 | 11:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TD Cowen has upgraded Ascendis Pharma from Hold to Buy and increased the price target from $156 to $175, indicating a positive outlook on the stock.
The upgrade from Hold to Buy and the increased price target suggest that TD Cowen sees significant upside potential in Ascendis Pharma's stock. This is likely to attract more investors and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100